Purification and Antioxidant and Anti-Inflammatory Activity of Extracellular Polysaccharopeptide from the Submerged Fermentation of Sanghuang Mushroom, Sanghuangporus lonicericola
Background: Sanghuang medicinal mushroom fungus is widely used in East Asia. In this study, antioxidant activity and anti-inflammatory properties of the new extracellular polysaccharopeptide (SePSP) was investigated. SePSP purified from the fermentation broth of the mycelium Sanghuang submerged, Sanghuangporus lonicericola stain Sanghuang CBS17 isolated from wild fruit body.
Results: SePSP extracted using ethanol precipitation procedures, followed by anion exchange and size-exclusion chromatography DEAE. The mass ratio of polysaccharides and peptides in SePSP purified component is about 4.87: 1. In determining the ability of free radicals by using DPPH, hydroxyl free radical, and superoxide anion free radicals, as well as reducing overall power, SePSP have strong antioxidant activity in a concentration-dependent vitro. Furthermore, SePSP effectively reduced dextran sulfate sodium (DSS) induced ulcerative colitis (UC) in mice.
Administration of 200 mg / kg SePSP by gavage for 7 days to prevent loss of weight; significantly reduced the mRNA levels of proinflammatory cytokines including, TNF-α and IL-1β; an increase in mRNA levels of anti-inflammatory cytokine IL-10 in the colon; and a decrease in malondialdehyde concentration of 6.42 to 4.82 umol / L in the blood at UC rats.
Conclusion: SePSP have strong antioxidant activity in vitro concentration-dependent and effectively reduced DSS-induced UC in mice. In vivo therapeutic efficacy in DSS-induced UC can be mediated through the modulation of the expression of inflammatory cytokines and inhibit oxidative stress. The findings provide a scientific rationale for utilizing the bioactive nutraceuticals from Sanghuang fungus to develop functional foods for the prevention and treatment of UC. This article is protected by copyright. All copyrights
Purification and Antioxidant and Anti-Inflammatory Activity of Extracellular Polysaccharopeptide from the Submerged Fermentation of Sanghuang Mushroom, Sanghuangporus lonicericola
The clinical utility of Highly Sensitive Lateral Flow Immunoassay determined by Titer Analysis for the Detection of anti-SARS-CoV-2 antibodies in the Point-of-Care
Coronavirus disease in 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), becoming a pandemic in early 2020. The lateral flow immunoassay for antibody testing has been seen as a cheap and fast method for determining deployable previous infection with SARS-CoV-2; However, these tests have shown low sensitivity can not be accepted.
We report a lateral flow immunoassay nine currently available and compare the sensitivity of their titers in serum to best practices enzyme-linked immunosorbent assay (ELISA) and virus neutralization assay. PCR positive for a small group, we found two devices with lateral flow immunoassay sensitivity is approximately equal titers by ELISA; This device is positive for all PCR-positive patients keep SARS-CoV-2 neutralizing antibodies. One of these devices are placed in northern Italy to test the sensitivity and specificity of the real-world clinical settings. Using the device with a fingerstick blood in a cohort of 27 patients hospitalized PCR-positive and seven controls were hospitalized, ROC curve analysis gives AUC value of 0.7646 for IgG.
Description: Description of target: Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate. The LIF was mapped gene to 22q11-q12.2 by Southern analysis of a series of mouse/human somatic cell hybrids and by in situ hybridization to the chromosomes of 2 normal males and some individuals with chromosomal rearrangements. The gene maps between the Philadelphia translocation BCR1 and the breakpoint of the translocation in cell line GM2324 at 22q12.2. LIF derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to the cytokine include: the growth promotion and cell differentiation of different types of target cells, influence on bone metabolism, cachexia, neural development, embryogenesis and inflammation.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml
Description: Description of target: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.039 ng/mL
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.
Description: A polyclonal antibody against LIF. Recognizes LIF from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000
Description: A polyclonal antibody against LIF. Recognizes LIF from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:10000, IHC:1:25-1:100
Description: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface.
Description: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface.
Description: LIF is a pleiotropic cytokine produced at the maternal-fetal interface which has been shown to play an essential role in implantation in mice. It is produced in high amounts by the human endometrium and the trophoblast itself, and its receptors are present on cytotrophoblast cells. LIF could thus play a role in modulating HLA-G production and immune tolerance at the maternal-fetal interface. The gene maps to 22q11-q12.2, between the Philadelphia translocation BCR gene and the breakpoint of the translocation in cell line GM2324 at 22q12.2.
Description: LIF is a pleiotropic cytokine produced at the maternal-fetal interface which has been shown to play an essential role in implantation in mice. This gene is mapped to 22q11-q12.2, between the Philadelphia translocation BCR gene and the breakpoint of the translocation in cell line GM2324 at 22q12.2. LIF is produced in high amounts by the human endometrium and the trophoblast itself, and LIF receptors are present on cytotrophoblast cells. It could, thus, play a role in modulating HLA-G production and immune tolerance at the maternal-fetal interface.
Description: Quantitativesandwich ELISA kit for measuring Mouse Leukemia inhibitory factor, LIF in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Mouse Leukemia inhibitory factor, LIF in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich CLIA kit for quantitative measurement of Mouse LIF (Leukemia Inhibitory Factor) in samples from Serum, Plasma, Cell supernatant
ELISA kit for Mouse LIF (Leukemia Inhibitory Factor)
Description: A sandwich ELISA kit for quantitative measurement of Mouse LIF (Leukemia Inhibitory Factor) in samples from Serum, Plasma, Cell supernatant
LIF Leukemia Inhibitory Factor Mouse Recombinant Protein
Description: Leukemia Inhibitory Factor (LIF) Murine Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 181 amino acids and having a molecular mass of 20 kDa. ;The Leukemia Inhibitory Factor (LIF) is purified by proprietary chromatographic techniques.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF
Description: LIFR also known as CD118 (Cluster of Differentiation 118), is a subunit of a receptor for leukemia inhibitory factor. This gene encodes a protein that belongs to the type I cytokine receptor family. This protein combines with a high-affinity converter subunit, gp130, to form a receptor complex that mediates the action of the leukemia inhibitory factor, a polyfunctional cytokine that is involved in cellular differentiation, proliferation and survival in the adult and the embryo. Mutations in this gene cause Schwartz-Jampel syndrome type 2, a disease belonging to the group of the bent-bone dysplasias. A translocation that involves the promoter of this gene, t(5;8)(p13;q12) with the pleiomorphic adenoma gene 1, is associated with salivary gland pleiomorphic adenoma, a common type of benign epithelial tumor of the salivary gland. Multiple splice variants encoding the same protein have been found for this gene.
Description: The protein encoded by this gene is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF (Center). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF (Internal). This antibody is tested and proven to work in the following applications:
Lif sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
As a comparison, this test was also tested with saliva from the same patient population and showed a decrease in discrimination between cases and controls with AUC values of 0.6841 for IgG. In addition, during a virus neutralization test, the patients were found to harbor autoantibodies to ACE2, with implications for how the immune response is profiled. We show here through the study proof-of-concept that a lateral flow device can be as analytical as sensitive as ELISA and adopted into hospital protocol; However, additional improvements to these devices is still required before their clinical deployment.
